Andreas Argyrides's Stock Ratings

Overall Average Return

25.8%

Smart Score

Overall Average Return Percentile

85th

Number of Ratings

1

		Buy Now								Get Alert
12/19/2023	GOSS	Buy Now	Gossamer Bio	$3.88	54.64%	Andreas Argyrides75%	$6 → $6	Reiterates	Outperform → Outperform	Get Alert

Recent Analyst Stock Rating News

12 Analysts Have This To Say About Liquidia

FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers

FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers

Sarepta stock sees upgrades and price hikes as analysts reassess Elevidys prospects following a favorable FDA development.

6 Analysts Assess Harmony Biosciences Hldgs: What You Need To Know

6 Analysts Assess Harmony Biosciences Hldgs: What You Need To Know

Where Harmony Biosciences Hldgs Stands With Analysts

Where Harmony Biosciences Hldgs Stands With Analysts

Breaking Down Liquidia: 12 Analysts Share Their Views

Breaking Down Liquidia: 12 Analysts Share Their Views

This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

Forecasting The Future: 7 Analyst Projections For Keros Therapeutics

Forecasting The Future: 7 Analyst Projections For Keros Therapeutics

Analyst Expectations For Keros Therapeutics's Future

Analyst Expectations For Keros Therapeutics's Future

Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings)

Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings)

Where Keros Therapeutics Stands With Analysts

Where Keros Therapeutics Stands With Analysts

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

Benzinga Pro on Macbook